Christopher Dinsmore has joined Kronos Bio as its chief scientific officer. He was most recently entrepreneur in residence at venture capital firm Third Rock Ventures. His experience also includes roles at Forma Therapeutics and Merck (NYSE: [[ticker:MRK]]). Kronos launched nearly a year ago with a $105 million Series A round of financing. The San Mateo, CA-based biotech is developing cancer drugs that address proteins considered “undruggable.”
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
